After participating in this educational activity, attendees should be able to:
1. Understand the measurement of outcomes in the treatment of radioiodine-refractory thyroid cancer
2. Describe the common toxicities of tyrosine kinase inhibitors used in the therapy of thyroid cancer
3. Describe the commonly used TKIs in thyroid cancer management


Wilson C. Mertens, MD, MSBA
Vice President and Medical Director, Cancer Services
Chief, Division of Hematology Oncology
Baystate Medical Center 

Faculty Disclosure
None of the members of the faculty and planning committee for this educational event have commercial relationships with any entity producing, marketing, re-selling or distributing health care goods and services consumed by or used on patients.

Session date: 
10/08/2019 - 12:00pm to 1:00pm EDT
Baystate Medical Center
759 Chestnut Street
Springfield, MA 01199
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC Contact Hours
  • 1.00 BCIPE Instructional Hours

Please login or register to take this course.